EP2764116B1 - Mit venöser thrombose bei frauen assoziierte genetische polymorphismen, nachweisverfahren und ihre verwendung - Google Patents

Mit venöser thrombose bei frauen assoziierte genetische polymorphismen, nachweisverfahren und ihre verwendung Download PDF

Info

Publication number
EP2764116B1
EP2764116B1 EP12769657.3A EP12769657A EP2764116B1 EP 2764116 B1 EP2764116 B1 EP 2764116B1 EP 12769657 A EP12769657 A EP 12769657A EP 2764116 B1 EP2764116 B1 EP 2764116B1
Authority
EP
European Patent Office
Prior art keywords
polymorphism
snp
venous thrombosis
primer
genotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP12769657.3A
Other languages
English (en)
French (fr)
Other versions
EP2764116A1 (de
Inventor
Rainer Bernd ZOTZ
Rüdiger SCHARF
Andrea Gerhardt
Daniel Szafarczyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scharf Ruediger Eberhard
Original Assignee
Scharf Ruediger Eberhard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scharf Ruediger Eberhard filed Critical Scharf Ruediger Eberhard
Priority to EP12769657.3A priority Critical patent/EP2764116B1/de
Publication of EP2764116A1 publication Critical patent/EP2764116A1/de
Application granted granted Critical
Publication of EP2764116B1 publication Critical patent/EP2764116B1/de
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • the present invention relates to the field of diagnosing and treating thrombosis. More specifically, the present invention relates to specific polymorphisms in the genome of women, and to the association of these polymorphisms with venous thrombosis in women. Based on the allele frequencies described herein, the naturally occurring polymorphisms that are disclosed herein are associated with venous thrombosis in women, and can be used for assessing a woman's risk of developing venous thrombosis, for early detection of venous thrombosis in a woman, for providing clinically relevant information for preventing venous thrombosis, and for providing a kit for use in assessing a woman's risk of developing venous thrombosis. Methods, assays, kits and reagent for detecting the presence of these polymorphisms are provided.
  • Thrombosis is the formation of a blood clot inside a blood vessel, wherein said clot obstructs the flow of blood through said blood vessel. If the thrombus occupies more than 75% of the diameter of an artery, the blood flow through this artery is reduced that much causing clinical symptoms due to the decreased oxygen supply of the tissue that should be supplied. In addition, metabolic products such as lactic acid accumulate. An obstruction of more than 90% of an artery's diameter will result in anoxia, infarction and tissue necrosis. When a clot breaks free, the traveling clot is called an embolus. The embolus may lodge in and obstruct a blood vessel somewhere behind the initial occlusion.
  • Venous thrombosis denotes the formation of a blood clot in a vein.
  • venous thrombosis Several diseases may be classified as venous thrombosis: deep vein thrombosis, portal vein thrombosis, renal vein thrombosis, jugular vein thrombosis, Budd-Chiari-Syndrome, Paget-von-Schroetter syndrome, and cerebral sinus venous thrombosis.
  • a venous thrombosis is a chronic and polygenic disease. Approximately 1 ⁇ of US citizens encounter a venous thrombotic event for the first time each year resulting in over 200,000 new cases annually. Roughly, 30% of these patients die within three days.
  • prothrombotic risk factors for determining thromboprophylaxis and -therapy in individuals is highlighted in e.g. Gould M.K. et al., Chest, 2012, 141(2) supplement: e227S-e277S .
  • providing new tools as suitable risk factors allow more specific and suitable stratification of the risk of venous thrombosis.
  • specific groups of individuals e.g. in women at an age of over 50 years, require specific marker molecules for identifying higher risk of venous thrombosis in said individuals.
  • Venous thrombosis is a multi-factorial disease resulting from acquired factors and genetic factors. For the latter, there is a need for genetic markers that are predictive of a person's predisposition to venous thrombosis such that humans having an increased risk of developing venous thrombosis can be identified and prophylactically treated.
  • WO 2008/051511 A2 discloses genetic polymorphisms that are associated with venous thrombosis, and describes methods of detecting these polymorphisms, and of using these polymorphisms.
  • the claimed method comprises detecting a single nucleotide polymorphism as specified in any one of 146 specific nucleotide sequences or complements thereof, wherein the presence of the single nucleotide polymorphism is indicative of an altered risk for venous thrombosis.
  • Venous thromboses occur more often in elderly patients and constitute an important problem in health care policies.
  • the pathomechanism of an increased likelihood of encountering a venous thrombosis event at later ages is insufficiently discovered. Therefore, there is a need for additional and/or alternative genetic markers that are indicative for the predisposition of an elderly person to develop venous thrombosis. It is known that the activity of Factor IX increases with a person's age, and Kurachi et al. ( Kurachi S. et al,, Science, 1999, 285: 739-743 ; Kurachi K, Kurachi. J Thromb Haemost.
  • Factor IX is a serine protease of the peptidase S1 family.
  • Factor IX is synthesized as an inactive precursor protein that is activated in that its signal peptide is removed, and the resulting preprotein is subsequently cleaved into two subunits which are linked to one another by a disulfide bond. The cleavage into its two subunits is performed either by factor XIa or by factor VIIa. The cleavage into its two subunits activates factor IX into factor IXa.
  • Factor IXa in turn hydrolyses factor X of the coagulation cascade into factor Xa in the presence of Ca 2+ , membrane lipids and cofactor VIII.
  • the factor IX-gene also designated as factor 9-gene, contains the genetic code for clotting factor IX.
  • the factor IX-gene is located on the long arm of the X-chromosome, and has a length of approximately 32,000 base pairs.
  • the genetic code for clotting factor IX is distributed to 8 exons. Its 7 introns account for 92% of the length of the factor IX-gene.
  • the single nucleotide polymorphism database (dbSNP) of the National Center for Biotechnology Information (NCBI) describes approximately 200 polymorphisms within the factor IX gene. However, only one of those polymorphisms was associated with an alteration of the risk of developing thrombosis. Bezemer et al.
  • factor IX - Padua Another rare mutation of factor IX gene, factor IX - Padua, is supposed to be associated with a person's risk of developing a thrombosis.
  • Simioni et al. Simioni P, et al., N Engl J Med. 2009, 361: 1671-1675 ) identified a mutation in exon 8 of the factor IX-gene, the wild type allele "G" was replaced with allele "T", in a patient suffering from thrombosis. That patient exhibited increased factor IX activity, and it was also shown in-vitro that factor IX - Padua is associated with an increased activity of factor IX activity.
  • factor IX - Padua is a rare mutation.
  • coagulation factor IX was investigated for identifying genetic variations that are associated with age-related effects, and to identify genetic variants which constitute a risk factor with respect to thrombosis in elderly persons.
  • F9 factor 9
  • two genetic variants of the factor 9 (F9) gene namely genotype AA of the F9 G32023A polymorphism (rs440051) and genotype GT6/GT6 of the F9 5:32164:6/4 polymorphism (rs35599944), which are correlated with one another and which are in a linkage disequilibrium, are associated with a strong, e.g. an eleven-fold increase of the risk of women to encounter a thrombolic event.
  • the first polymorphism refers to registration number rs440051 within the single nucleotide polymorphism database of the NCBI.
  • the first polymorphism is designated F9 G32023A for specific non-limiting embodiments of the present invention.
  • the number 32023 within this designation identifies the position of the polymorphism within the Homo sapiens X-chromosome, beginning with the first nucleotide of the Factor IX (F9) gene, i.e.
  • number 1 represents the first nucleotide of the first exon of the Factor IX-gene, with respect to reference sequence NC_000023.9 (gi:89161218, Homo sapiens chromosome X, reference assembly, complete sequence: NCBI) of the X-chromosome.
  • the Factor IX-gene is positioned from nucleotide 138440561 to nucleotide 138473283 within said X-chromosome reference sequence NC_000023.9.
  • the other polymorphism refers to registration number rs35599944 within the single nucleotide polymorphism database of the NCBI.
  • This polymorphism is designated F9 5:32164:6/4 for specific non-limiting embodiments of the present invention.
  • the number 32164 within this designation identifies the position of the polymorphism within the Homo sapiens X-chromosome, beginning with the first nucleotide of the Factor IX (F9) gene, i.e.
  • polymorphism rs35599944 begins 141 bp downstream of polymorphism rs440051 as can be inferred from SEQ ID No: 6 which represents a fragment of the Homo sapiens Factor IX-gene including polymorphisms rs440051 and rs35599944.
  • both polymorphisms are correlated with one another. That means, both polymorphism are detectable in combination only and being in strong linkage disequilibrium. Hence, it is sufficient to detect at least one out of the two polymorphisms according to the present invention, since both SNPs are equally suitable.
  • the invention concerns a method for identifying a woman who has an increased risk of developing venous thrombosis, the method comprises detecting the presence of at least one of the genotype AA of the F9 G32023A polymorphism, and the genotype GT6/GT6 of the F9 5:32164:6/4 polymorphism, wherein the presence of either of said genotypes or the presence of both of said genotypes is indicative for the increased risk for venous thrombosis in said woman.
  • the invention concerns a method for identifying a woman who is in need of receiving therapeutically or prophylactic treatment of venous thrombosis, comprising detecting the presence of at least one of the genotype AA of the F9 G32023A polymorphism, and the presence of the genotype GT6/GT6 of the F9 5:32164:6/4 polymorphism.
  • the invention concerns a kit for use in identifying a woman who has an increased risk for developing venous thrombosis by detecting the presence of genotype AA of the F9 G32023A polymorphism, and/or the presence of the genotype GT6/GT6 of the F9 5:32164:6/4 polymorphism.
  • the methods are in vitro _methods.
  • the methods according to the present invention may be in vitro _methods wherein samples of the subjects, in particular, of the women, are provided. Said samples include samples from body fluid, like urine, blood or sputum or samples obtained from tissue.
  • the invention concerns a method for identifying a woman having an increased risk of developing venous thrombosis, the method comprises genotyping the woman with respect to at least one of the F9 G32023A polymorphism and the F9 5:32164:6/4 polymorphism, wherein detecting the presence of the genotype AA of the F9 G32023A polymorphism and/or the genotype GT6/GT6 of the F9 5:32164:6/4 polymorphism is indicative for an increased risk for developing venous thrombosis.
  • the method for identifying a woman having an increased risk of developing venous thrombosis is a method for identifying a woman's risk of developing venous thrombosis at an age of above 50 years.
  • the invention concerns a method for identifying a woman who may benefit from or is in need of prophylactic or therapeutic treatment of venous thrombosis e.g. due to an increased risk of developing venous thrombosis, the method comprises genotyping the woman with respect to at least one of the F9 G32023A polymorphism and/or the F9 5:32164:6/4 polymorphism, wherein detecting the presence of the genotype AA of the F9 G32023A polymorphism and/or the genotype GT6/GT6 of the F9 5:32164:6/4 polymorphism is indicative for a particular prophylactic or therapeutic treatment of venous thrombosis, e.g. due to an increased risk of developing venous thrombosis.
  • the method for identifying a woman who may benefit from or is in need of prophylactic or therapeutic treatment of venous thrombosis is a method for identifying a woman who has an increased risk of developing venous thrombosis at an age of above 50 years.
  • the embodiment is particularly a method for identifying a woman who may particularly benefit from or is in need of prophylactic or therapeutic treatment of venous thrombosis at an age of 50 years or older.
  • the method comprises detection of both the genotypes AA of the F9 G32023A polymorphism and GT6/GT6 of the F9 5:32164:6/4 polymorphism.
  • the detection involves a method selected from the group consisting of hybridization-based assays, PCR-based assays, primer extension reactions, sequencing reactions, allele-specific probe hybridization, allele-specific primer extension, allele-specific amplification, sequencing, 5' nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, and single-stranded conformation polymorphism.
  • the method comprises using, e.g. taking, a test sample of the woman.
  • genomic DNA of the woman to be risk assessed is used for detecting the genotyping.
  • the present invention provides a kit for use in identifying a woman who has an increased risk of developing venous thrombosis.
  • Said kit is adapted for detecting the presence of at least one of the genotype AA of the F9 G32023A polymorphism and of the genotype GT6/GT6 of the F9 5:32164:6/4 polymorphism within the genome of a woman.
  • identifying refers to determining the genotype of the subject and based on the genotype determing whether the subject is at an increased risk of developing venous thrombosis. The term includes diagnosing said subject.
  • the kit comprises at least one "SNP detection reagent” for detecting at least one of the SNPs as specified in any one of SEQ ID NO: 1 to 5, or a complement thereof.
  • a "SNP detection reagent” is a reagent which specifically detects a specific target SNP that is selected from the group consisting of the F9 G32023A polymorphism and the F9 5:32164:6/4 polymorphism.
  • the SNP detection reagent is specific for a particular nucleotide (allele) of one of said target SNP positions.
  • the SNP detection reagent can differentiate between different alternative nucleotides at a given target SNP position or between different numbers of dinucleotides at a target SNP position, thereby allowing to identify the nucleotide(s) present at the target SNP site to be determined.
  • the SNP detection reagent hybridizes to a target SNP-containing nucleic acid molecule by complementary base-pairing in a sequence-specific manner, and discriminates the target variant from other nucleic acid molecules comprising different nucleotide sequences.
  • the SNP detection reagent can differentiate between nucleic acids having a particular nucleotide (allele) at a target SNP position from other nucleic acids that have a different nucleotide at the same SNP target position.
  • a SNP detection reagent is a DNA or RNA oligonucleotide probe or primer or PNA oligomer, or a combination thereof, that hybridizes to a segment of a target nucleic acid molecule containing a SNP as specified in any one of SEQ ID NO: 1 to 5.
  • the DNA or RNA oligonucleotide probe or primer is an isolated or synthetic DNA or RNA molecule.
  • the SNP detection reagent in form of a polynucleotide may contain modified base analogs, intercalators or minor groove binders.
  • SNP detection reagents such as probes may be, for example, affixed to a solid support such as an array or beads, or the SNP detection reagents may be supplied in solution (e.g. probe/primer sets for enzymatic reactions such as PCR, RT-PCR, TaqMan assays, or primer-extension reactions) to form a SNP detection kit.
  • the probe or primer is a purified oligonucleotide or PNA oligomer.
  • oligonucleotide typically comprises a region of complementary nucleotide sequence that hybridizes under stringent conditions to at least 8, 10, 12, 16, 18, 20, 22, 25, 30, 40, 50, 55, 60, 65, 70, 80, 90, 100, 120 (or any number in-between) or more consecutive nucleotides in a target nucleic acid molecule.
  • the target nucleic acid molecule is a nucleic acid molecule, preferably a DNA molecule, which comprises at least one of the F9 G32023A polymorphism and the GT6/GT6 of the F9 5:32164:6/4 polymorphism.
  • the consecutive nucleotides can either include one of the target SNP positions, or be a specific region in close proximity 5' and/or 3' of the SNP position to carry out the desired assay.
  • primer and probe sequences can readily be determined using the transcript sequences, genomic sequences and SNP context sequences disclosed in SEQ ID NO: 6, genomic based context sequences, and complements thereof. It will be apparent to one of skill in the art that such primers and probes are directly useful as reagents for genotyping the SNPs of the present invention, and can be incorporated into any kit/system format.
  • a primer or probe of the present invention has preferably a length of at least 8 nucleotides. More preferably, the primer or a probe has a length of at least 10 nucleotides. Even more preferably, the primer or a probe has a length of at least 12 nucleotides. Most preferably, the primer or probe has a length of at least 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotide. While the maximal length of a probe can be as long as the target sequence to be detected, depending on the type of assay in which it is employed, it is typically less than about 50, 60, 65, or 70 nucleotides in length. In the case of a primer, it is typically less than 30 nucleotides in length. In a specific preferred embodiment of the invention, a primer or a probe is within the length of 18 and 28 nucleotides.
  • the probes can be longer, such as on the order of 30 to 70, 75, 80, 90, 100, or more nucleotides in length.
  • oligonucleotides specific for alternative SNP alleles For analyzing the SNPs or the invention, it is advantageous to use oligonucleotides specific for alternative SNP alleles.
  • Such oligonucleotides that detect single nucleotide variations in target sequences may be referred to by such terms as “allele-specific oligonucleotides”, “allele-specific probes”, or “allele-specific primers”. While the design of each allele-specific primer or probe depends on variables such as the precise composition of the nucleotide sequences flanking a SNP position in a target nucleic acid molecule, and the length of the primer or probe, another factor in the use of primers and probes is the stringency of the condition under which the hybridization between the probe or primer and the target sequence is performed.
  • Higher stringency conditions utilize buffers with lower ionic strength and/or a higher reaction temperature, and tend to require a more perfect match between probe/primer and a target sequence in order to form a stable duplex. If the stringency is too high, however, hybridization may not occur at all.
  • lower stringency conditions utilize buffers with higher ionic strength and/or a lower reaction temperature, and permit the formation of stable duplexes with more mismatched bases between a probe/primer and a target sequence.
  • exemplary conditions for high stringency hybridization conditions using an allele-specific probe are as follows: prehybridization with a solution containing 5X standard saline phosphate EDTA (SSPE), 0.5% NaDodSO 4 (SDS) at 55°C, and incubating probe with target nucleic acid molecules in the same solution at the same temperature, followed by washing with a solution containing 2X SSPE, and 0.1%SDS at 55°C or room temperature.
  • SSPE standard saline phosphate EDTA
  • SDS NaDodSO 4
  • Moderate stringency hybridization conditions may be used for allele-specific primer extension reactions with a solution containing, e.g., about 50 mM KCl at about 46°C.
  • the reaction may be carried out at an elevated temperature such as 60°C.
  • a moderately stringent hybridization condition suitable for oligonucleotide ligation assay (OLA) reactions wherein two probes are ligated if they are completely complementary to the target sequence may utilize a solution of about 100 mM KCl at a temperature of 46°C.
  • allele-specific probes can be designed that hybridize to a segment of the target nucleic acid molecule from one individual but do not hybridize to the corresponding segment from another individual due to the presence of different polymorphic forms of the SNP target sites (e.g., alternative SNP alleles/nucleotides) in the respective DNA segments from the two individuals.
  • Hybridization conditions should be sufficiently stringent that there is a significant detectable difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles or significantly more strongly to one allele.
  • a probe may be designed to hybridize to a target sequence that contains a SNP site such that the SNP site aligns anywhere along the sequence of the probe
  • the probe is preferably designed to hybridize to a segment of the target sequence such that the SNP site aligns with a central position of the probe (e.g., a position within the probe that is at least three nucleotides from either end of the probe).
  • This design of probe generally achieves good discrimination in hybridization between different allelic forms.
  • a probe or primer may be designed to hybridize to a segment of target nucleic acid molecule such that the SNP aligns with either the 5' most end or the 3' most end of the probe or primer.
  • the 3' most nucleotide of the probe aligns with the SNP position in the target sequence.
  • Oligonucleotide probes and primers may be prepared by methods well known in the art. In the case of an array, multiple pairs of probes can be immobilized on the same support for simultaneous analysis of multiple different polymorphisms.
  • an allele-specific primer hybridizes to a region on a target nucleic acid molecule that overlaps a SNP position and only primes amplification of an allelic form to which the primer exhibits perfect complementarity.
  • the primer's 3'-most nucleotide is aligned with and complementary to the SNP position of the target nucleic acid molecule.
  • This primer is used in conjunction with a second primer that hybridizes at a distal site. Amplification proceeds from the two primers, producing a detectable product that indicates which allelic form is present in the test sample.
  • a control is usually performed with a second pair of primers, one of which shows a single base mismatch at the polymorphic site and the other of which exhibits perfect complementarity to a distal site.
  • the single-base mismatch prevents amplification or substantially reduces amplification efficiency, so that either no detectable product is formed or it is formed in lower amounts or at a slower pace.
  • the method generally works most effectively when the mismatch is at the 3'-most position of the oligonucleotide (i.e., the 3'-most position of the oligonucleotide aligns with the target SNP position) because this position is most destabilizing to elongation from the primer.
  • This PCR-based assay can be utilized as part of the TaqMan assay, described below.
  • a primer of the invention contains a sequence substantially complementary to a segment of a target SNP-containing nucleic acid molecule except that the primer has a mismatched nucleotide in one of the three nucleotide positions at the 3'-most end of the primer, such that the mismatched nucleotide does not base pair with a particular allele at the SNP site.
  • the mismatched nucleotide in the primer is the second from the last nucleotide at the 3'-most position of the primer.
  • the mismatched nucleotide in the primer is the last nucleotide at the 3'-most position of the primer.
  • a SNP detection reagent of the invention is labeled with a fluorogenic reporter dye that emits a detectable signal.
  • a fluorogenic reporter dye that emits a detectable signal.
  • the preferred reporter dye is a fluorescent dye
  • any reporter dye that can be attached to a detection reagent such as an oligonucleotide probe or primer is suitable for use in the invention.
  • Such dyes include, but are not limited to, Acridine, AMCA, BODIPY, Cascade Blue, Cy2, Cy3, Cy5, Cy7, Dabcyl, Edans, Eosin, Erythrosin, Fluorescein, 6-Fam, Tet, Joe, Hex, Oregon Green, Rhodamine, Rhodol Green, Tamra, Rox, and Texas Red.
  • the detection reagent may be further labeled with a quencher dye such as Tamra, especially when the reagent is used as a self-quenching probe such as a TaqMan or Molecular Beacon probe, or other stemless or linear beacon probe.
  • a quencher dye such as Tamra
  • the SNP detection reagents of the invention may also contain other labels, including but not limited to, biotin for streptavidin binding, hapten for antibody binding, and oligonucleotide for binding to another complementary oligonucleotide such as pairs of zipcodes.
  • the present invention also contemplates SNP detection reagents that do not contain (or that are complementary to) a SNP nucleotide identified herein but that are used to assay one or more SNPs disclosed herein.
  • SNP detection reagents that do not contain (or that are complementary to) a SNP nucleotide identified herein but that are used to assay one or more SNPs disclosed herein.
  • primers that flank, but do not hybridize directly to a target SNP position provided herein are useful in primer extension reactions in which the primers hybridize to a region adjacent to the target SNP position (i.e., within one or more nucleotides from the target SNP site).
  • a primer is typically not able to extend past a target SNP site if a particular nucleotide (allele) is present at that target SNP site, and the primer extension product can be detected in order to determine which SNP allele is present at the target SNP site.
  • particular ddNTPs are typically used in the primer extension reaction to terminate primer extension once a ddNTP is incorporated into the extension product (a primer extension product which includes a ddNTP at the 3'-most end of the primer extension product, and in which the ddNTP is a nucleotide of a SNP disclosed herein, is a composition that is specifically contemplated by the present invention).
  • reagents that bind to a nucleic acid molecule in a region adjacent to a SNP site and that are used for assaying the SNP site, even though the bound sequences do not necessarily include the SNP site itself, are also contemplated by the present invention.
  • kits can be developed and used to assay any SNP of the present invention individually or in combination, and that a kit may comprise these SNP detection reagents.
  • kit and “kits”, as used herein in the context of SNP detection reagents, are intended to also refer to such things as combinations of multiple SNP detection reagents, or one or more SNP detection reagents in combination with one or more other types of elements or components (e.g., other types of biochemical reagents, containers, packages such as packaging intended for commercial sale, substrates to which SNP detection reagents are attached, electronic hardware components, etc.).
  • the present invention further provides SNP detection kits, including but not limited to, packaged probe and primer sets (e.g., TaqMan probe/primer sets), arrays/microarrays of nucleic acid molecules, and beads that contain one or more probes, primers, or other detection reagents for detecting one or more SNPs of the present invention.
  • packaged probe and primer sets e.g., TaqMan probe/primer sets
  • arrays/microarrays of nucleic acid molecules e.g., aqMan probe/primer sets
  • beads that contain one or more probes, primers, or other detection reagents for detecting one or more SNPs of the present invention.
  • the kits/systems can optionally include various electronic hardware components; for example, arrays ("DNA chips") and microfluidic systems ("lab-on-a-chip” systems) provided by various manufacturers typically comprise hardware components.
  • kits/systems may not include electronic hardware components, but may be comprised of, for example, one or more SNP detection reagents (along with, optionally, other biochemical reagents) packaged in one or more containers.
  • a SNP detection kit may further contain one or more other components (e.g., at least one buffer, one or more enzymes such as DNA polymerases or ligases, chain extension nucleotides such as deoxynucleotide triphosphates, and in the case of Sanger-type DNA sequencing reactions, chain terminating nucleotides, positive control sequences, negative control sequences, and the like) necessary to carry out an assay or reaction, such as amplification and/or detection of a SNP-containing nucleic acid molecule.
  • one or more other components e.g., at least one buffer, one or more enzymes such as DNA polymerases or ligases, chain extension nucleotides such as deoxynucleotide triphosphates, and in the case of Sanger-type DNA sequencing reactions, chain terminating nucleotides, positive control sequences, negative control sequences, and the like.
  • kits may further contain means for determining the amount of a target nucleic acid, and means for comparing the amount with a standard, and can comprise instructions for using the kit to detect the SNP-containing nucleic acid molecule of interest.
  • kits are provided which contain the necessary reagents to carry out one or more assays to detect one or more SNPs disclosed herein.
  • SNP detection kits/systems are in the form of nucleic acid arrays, or compartmentalized kits, including microfluidic/lab-on-a-chip systems.
  • the kit for use in identifying a woman having an increased risk of developing venous thrombosis may contain, for example, one or more probes, or pairs of probes, that hybridize to a nucleic acid molecule at or near each target SNP position.
  • Multiple pairs of allele-specific probes may be included in the kit to simultaneously assay large numbers of SNPs, at least one of which is a SNP of the present invention.
  • multiple pairs of allele-specific probes are included in the kit to simultaneously assay both SNPs of the present invention.
  • the allele-specific probes are immobilized to a substrate such as an array or bead.
  • arrays are used herein interchangeably to refer to an array of distinct polynucleotides affixed to a substrate, such as glass, plastic, paper, nylon or other type of membrane, filter, chip, or any other suitable solid support.
  • a substrate such as glass, plastic, paper, nylon or other type of membrane, filter, chip, or any other suitable solid support.
  • the polynucleotides can be synthesized directly on the substrate, or synthesized separate from the substrate and then affixed to the substrate.
  • probes such as allele-specific probes
  • each probe or pair of probes can hybridize to a different SNP position.
  • polynucleotide probes they can be synthesized at designated areas (or synthesized separately and then affixed to designated areas) on a substrate using a light-directed chemical process.
  • Each DNA chip can contain, for example, thousands to millions of individual synthetic polynucleotide probes arranged in a gridlike pattern and miniaturized ⁇ e.g., to the size of a dime).
  • probes are attached to a solid support in an ordered, addressable array.
  • a microarray can be composed of a large number of unique, single-stranded polynucleotides, usually either synthetic antisense polynucleotides or fragments of cDNAs, fixed to a solid support.
  • Typical polynucleotides are preferably about 6-60 nucleotides in length, more preferably about 15-30 nucleotides in length, and most preferably about 18-25 nucleotides in length.
  • preferred probe lengths can be, for example, about 15-80 nucleotides in length, preferably about 50-70 nucleotides in length, more preferably about 55-65 nucleotides in length, and most preferably about 60 nucleotides in length.
  • the microarray or detection kit can contain polynucleotides that cover the known 5' or 3' sequence of a gene/transcript or target SNP site, sequential polynucleotides that cover the full-length sequence of a gene/transcript; or unique polynucleotides selected from particular areas along the length of a target gene/transcript sequence.
  • Polynucleotides used in the microarray or detection kit can be specific to a SNP or SNPs of interest (e.g., specific to a particular SNP allele at a target SNP site, or specific to particular SNP alleles at multiple different SNP sites), or specific to a polymorphic gene/transcript or genes/transcripts of interest.
  • Hybridization-based assays based on polynucleotide arrays rely on the differences in hybridization stability of the probes to perfectly matched and mismatched target sequence variants.
  • stringency conditions used in hybridization assays are high enough such that nucleic acid molecules that differ from one another at as little as a single SNP position can be differentiated (e.g., typical SNP hybridization assays are designed so that hybridization will occur only if one particular nucleotide is present at a SNP position, but will not occur if an alternative nucleotide is present at that SNP position).
  • Such high stringency conditions may be preferable when using, for example, nucleic acid arrays of allele-specific probes for SNP detection. Such high stringency conditions are described in the preceding section, and are well known to those skilled in the art.
  • the present invention provides methods of identifying the SNPs disclosed herein in a test sample. Such methods typically involve incubating a test sample of nucleic acids with an array comprising one or more probes corresponding to at least one SNP position of the present invention, and assaying for binding of a nucleic acid from the test sample with one or more of the probes. Conditions for incubating a SNP detection reagent (or a kit/system that employs one or more such SNP detection reagents) with a test sample vary. Incubation conditions depend on such factors as the format employed in the assay, the detection methods employed, and the type and nature of the detection reagents used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification and array assay formats can readily be adapted to detect the SNPs disclosed herein.
  • a SNP detection kit/system of the present invention may include components that are used to prepare nucleic acids from a test sample for the subsequent amplification and/or detection of a SNP-containing nucleic acid molecule.
  • sample preparation components can be used to produce nucleic acid extracts (including DNA and/or RNA), proteins or membrane extracts from any bodily fluids (such as blood, serum, plasma, urine, saliva, phlegm, gastric juices, semen, tears, sweat, etc.), skin, hair, cells (especially nucleated cells), biopsies, buccal swabs or tissue specimens.
  • test samples used in the above-described methods will vary based on such factors as the assay format, nature of the detection method, and the specific tissues, cells or extracts used as the test sample to be assayed.
  • Methods of preparing nucleic acids, proteins, and cell extracts are well known in the art and can be readily adapted to obtain a sample that is compatible with the system utilized.
  • Automated sample preparation systems for extracting nucleic acids from a test sample are commercially available, and examples are Qiagen's BioRobot 9600, Applied Biosystems' PRISMTM 6700 sample preparation system, and Roche Molecular Systems' COBAS AmpliPrep System.
  • kits contemplated by the present invention are a compartmentalized kit.
  • a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include, for example, small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allow one to efficiently transfer reagents from one compartment to another compartment such that the test samples and reagents are not cross-contaminated, or from one container to another vessel not included in the kit, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another or to another vessel.
  • Such containers may include, for example, one or more containers which will accept the test sample, one or more containers which contain at least one probe or other SNP detection reagent for detecting one or more SNPs of the present invention, one or more containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and one or more containers which contain the reagents used to reveal the presence of the bound probe or other SNP detection reagents.
  • wash reagents such as phosphate buffered saline, Tris-buffers, etc.
  • the kit can optionally further comprise compartments and/or reagents for, for example, nucleic acid amplification or other enzymatic reactions such as primer extension reactions, hybridization, ligation, electrophoresis (preferably capillary electrophoresis), mass spectrometry, and/or laser-induced fluorescent detection.
  • the kit may also include instructions for using the kit.
  • Exemplary compartmentalized kits include microfluidic devices known in the art. In such microfluidic devices, the containers may be referred to as, for example, microfluidic "compartments", "chambers", or "channels".
  • Microfluidic devices which may also be referred to as "lab-on-a-chip” systems, biomedical micro-electro-mechanical systems (bioMEMs), or multicomponent integrated systems, are exemplary kits/systems of the present invention for analyzing SNPs.
  • Such systems miniaturize and compartmentalize processes such as probe/target hybridization, nucleic acid amplification, and capillary electrophoresis reactions in a single functional device.
  • Such microfluidic devices typically utilize detection reagents in at least one aspect of the system, and such detection reagents may be used to detect one or more SNPs of the present invention.
  • One example of a microfluidic system comprises integration of PCR amplification and capillary electrophoresis in chips.
  • Exemplary microfluidic systems comprise a pattern of microchannels designed onto a glass, silicon, quartz, or plastic wafer included on a microchip.
  • the movements of the samples may be controlled by electric, electroosmotic or hydrostatic forces applied across different areas of the microchip to create functional microscopic valves and pumps with no moving parts. Varying the voltage can be used as a means to control the liquid flow at intersections between the micro-machined channels and to change the liquid flow rate for pumping across different sections of the microchip.
  • an exemplary microfluidic system may integrate, for example, nucleic acid amplification, primer extension, capillary electrophoresis, and a detection method such as laser induced fluorescence detection.
  • nucleic acid samples are amplified, preferably by PCR.
  • the amplification products are subjected to automated primer extension reactions using ddNTPs (specific fluorescence for each ddNTP) and the appropriate oligonucleotide primers to carry out primer extension reactions which hybridize just upstream of the targeted SNP.
  • the primers are separated from the unincorporated fluorescent ddNTPs by capillary electrophoresis.
  • the separation medium used in capillary electrophoresis can be, for example, polyacrylamide, polyethyleneglycol or dextran.
  • the incorporated ddNTPs in the single nucleotide primer extension products are identified by laser-induced fluorescence detection.
  • Such an exemplary microchip can be used to process, for example, at least 96 to 384 samples, or more, in parallel.
  • nucleic acid molecules described herein have a variety of uses, especially in relation to diagnosis and treatment of venous thrombosis in women.
  • the nucleic acid molecules are useful as hybridization probes, such as for genotyping SNPs in messenger RNA, transcript, cDNA, genomic DNA, amplified DNA or other nucleic acid molecules, and for isolating full-length cDNA and genomic clones as well as their orthologs.
  • a probe can hybridize to a region of a target sequence that encompasses SNP positions of the F9 G32023A polymorphism or of the GT6/GT6 of the F9 5:32164:6/4 polymorphism. More preferably, a probe hybridizes to a SNP-containing target sequence selected from the group consisting of the F9 G32023A polymorphism or the GT6/GT6 of the F9 5:32164:6/4 polymorphism in a sequence-specific manner such that it distinguishes the target sequence from other nucleotide sequences which vary from the target sequence only by which nucleotide is present at the SNP site.
  • Such a probe is particularly useful for detecting the presence of a SNP-containing nucleic acid in a test sample, or for determining which nucleotide (allele) is present at a particular SNP site (i.e., genotyping the SNP site).
  • a nucleic acid hybridization probe may be used for determining the presence, level, form, and/or distribution of nucleic acid expression.
  • the nucleic acid whose level is determined can be DNA or RNA.
  • probes specific for the SNPs described herein can be used to assess the presence, expression and/or gene copy number in a given cell, tissue, or organism. These uses are relevant for diagnosis of venous thrombosis in women or for assessing a woman's risk of developing venous thrombosis.
  • In vitro techniques for detection of mRNA include, for example, Northern blot hybridizations and in situ hybridizations.
  • In vitro techniques for detecting DNA include Southern blot hybridizations and in situ hybridizations.
  • nucleic acid molecules described herein can be used as hybridization probes to detect the SNPs disclosed herein, thereby determining whether an individual with the polymorphisms is at risk for venous thrombosis or has developed early stage venous thrombosis. Detection of a SNP associated with a disease phenotype provides a diagnostic tool for an active disease and/or genetic predisposition to the disease.
  • nucleic acid molecules are therefore useful for detecting a factor IX gene which contains a SNP disclosed herein and/or products of such genes, such as expressed mRNA transcript molecules, and are thus useful for detecting gene expression.
  • the nucleic acid molecules can optionally be implemented in, for example, an array or kit format for use in detecting gene expression.
  • nucleic acid molecules described herein are also useful as primers to amplify any given region of a nucleic acid molecule, particularly a region containing a SNP identified herein.
  • nucleic acid molecules described herein are also useful in assays for drug screening to identify compounds that, for example, modulate nucleic acid expression.
  • SNP genotyping The process of determining which specific nucleotide (i.e., allele) is present at each of one or both SNP positions is referred to as SNP genotyping.
  • Methods of SNP genotyping are described herein, such as for use in screening for venous thrombosis or related pathologies in women, or determining predisposition thereto, or determining responsiveness to a form of treatment, or in genome mapping or SNP association analysis, etc.
  • Nucleic acid samples can be genotyped to determine which allele(s) is/are present at any given genetic region (e.g., SNP position) of interest by methods well known in the art.
  • the neighboring sequence can be used to design SNP detection reagents such as oligonucleotide probes, which may optionally be implemented in a kit format.
  • Common SNP genotyping methods include, but are not limited to, TaqMan assays, molecular beacon assays, nucleic acid arrays, allele-specific primer extension, allele-specific PCR, arrayed primer extension, homogeneous primer extension assays, primer extension with detection by mass spectrometry, pyrosequencing, multiplex primer extension sorted on genetic arrays, ligation with rolling circle amplification, homogeneous ligation, OLA, multiplex ligation reaction sorted on genetic arrays, restriction-fragment length polymorphism, single base extension-tag assays, and the Invader assay.
  • Such methods may be used in combination with detection mechanisms such as, for example, luminescence or chemiluminescence detection, fluorescence detection, time-resolved fluorescence detection, fluorescence resonance energy transfer, fluorescence polarization, mass spectrometry, and electrical detection.
  • detection mechanisms such as, for example, luminescence or chemiluminescence detection, fluorescence detection, time-resolved fluorescence detection, fluorescence resonance energy transfer, fluorescence polarization, mass spectrometry, and electrical detection.
  • Various methods for detecting polymorphisms include, but are not limited to, methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes, comparison of the electrophoretic mobility of variant and wild type nucleic acid molecules, and assaying the movement of polymorphic or wild-type fragments in polyacrylamide gels containing a gradient of denaturant using denaturing gradient gel electrophoresis (DGGE). Sequence variations at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or chemical cleavage methods.
  • DGGE denaturing gradient gel electrophoresis
  • SNP genotyping is performed using the TaqMan assay, which is also known as the 5' nuclease assay.
  • the TaqMan assay detects the accumulation of a specific amplified product during PCR.
  • the TaqMan assay utilizes an oligonucleotide probe labeled with a fluorescent reporter dye and a quencher dye.
  • the reporter dye is excited by irradiation at an appropriate wavelength, it transfers energy to the quencher dye in the same probe via a process called fluorescence resonance energy transfer (FRET).
  • FRET fluorescence resonance energy transfer
  • the excited reporter dye does not emit a signal.
  • the proximity of the quencher dye to the reporter dye in the intact probe maintains a reduced fluorescence for the reporter.
  • the reporter dye and quencher dye may be at the 5' most and the 3' most ends, respectively, or vice versa.
  • the reporter dye may be at the 5' or 3' most end while the quencher dye is attached to an internal nucleotide, or vice versa.
  • both the reporter and the quencher may be attached to internal nucleotides at a distance from each other such that fluorescence of the reporter is reduced.
  • DNA polymerase cleaves the probe, thereby separating the reporter dye and the quencher dye and resulting in increased fluorescence of the reporter. Accumulation of PCR product is detected directly by monitoring the increase in fluorescence of the reporter dye.
  • the DNA polymerase cleaves the probe between the reporter dye and the quencher dye only if the probe hybridizes to the target SNP-containing template which is amplified during PCR, and the probe is designed to hybridize to the target SNP site only if a particular SNP allele is present.
  • Preferred TaqMan primer and probe sequences can readily be determined using the SNP and associated nucleic acid sequence information provided herein.
  • a number of computer programs such as Primer Express (Applied Biosystems, Foster City, CA), can be used to rapidly obtain optimal primer/probe sets. It will be apparent to one of skill in the art that such primers and probes for detecting the SNPs of the present invention are useful in diagnostic assays for VT and related pathologies, and can be readily incorporated into a kit format.
  • the present invention also includes modifications of the Taqman assay well known in the art such as the use of Molecular Beacon probes and other variant formats
  • Another preferred method for genotyping the SNPs of the present invention is the use of two oligonucleotide probes in an OLA.
  • one probe hybridizes to a segment of a target nucleic acid with its 3' most end aligned with the SNP site.
  • a second probe hybridizes to an adjacent segment of the target nucleic acid molecule directly 3' to the first probe.
  • the two juxtaposed probes hybridize to the target nucleic acid molecule, and are ligated in the presence of a linking agent such as a ligase if there is perfect complementarity between the 3' most nucleotide of the first probe with the SNP site. If there is a mismatch, ligation would not occur.
  • the ligated probes are separated from the target nucleic acid molecule, and detected as indicators of the presence of a SNP.
  • OLA is carried out prior to PCR (or another method of nucleic acid amplification). In other embodiments, PCR (or another method of nucleic acid amplification) is carried out prior to OLA.
  • Another method for SNP genotyping is based on mass spectrometry. Mass spectrometry takes advantage of the unique mass of each of the four nucleotides of DNA. SNPs can be unambiguously genotyped by mass spectrometry by measuring the differences in the mass of nucleic acids having alternative SNP alleles. MALDI-TOF (Matrix Assisted Laser Desorption Ionization - Time of Flight) mass spectrometry technology is preferred for extremely precise determinations of molecular mass, such as SNPs.
  • MALDI-TOF Microx Assisted Laser Desorption Ionization - Time of Flight
  • Preferred mass spectrometry-based methods of SNP genotyping include primer extension assays, which can also be utilized in combination with other approaches, such as traditional gel-based formats and microarrays.
  • the primer extension assay involves designing and annealing a primer to a template PCR amplicon upstream (5') from a target SNP position.
  • a mix of dideoxynucleotide triphosphates (ddNTPs) and/or deoxynucleotide triphosphates (dNTPs) are added to a reaction mixture containing template (e.g., a SNP-containing nucleic acid molecule which has typically been amplified, such as by PCR), primer, and DNA polymerase.
  • template e.g., a SNP-containing nucleic acid molecule which has typically been amplified, such as by PCR
  • primer e.g., a SNP-containing nucleic acid molecule which has typically been amplified, such as by PCR
  • DNA polymerase e.g., a SNP-containing nucleic acid molecule which has typically been amplified, such as by PCR
  • the primer can be either immediately adjacent (i.e., the nucleotide at the 3' end of the primer hybridizes to the nucleotide next to the target SNP site) or two or more nucleotides removed from the SNP position. If the primer is several nucleotides removed from the target SNP position, the only limitation is that the template sequence between the 3' end of the primer and the SNP position cannot contain a nucleotide of the same type as the one to be detected, or this will cause premature termination of the extension primer. Alternatively, if all four ddNTPs alone, with no dNTPs, are added to the reaction mixture, the primer will always be extended by only one nucleotide, corresponding to the target SNP position.
  • primers are designed to bind one nucleotide upstream from the SNP position (i.e., the nucleotide at the 3' end of the primer hybridizes to the nucleotide that is immediately adjacent to the target SNP site on the 5' side of the target SNP site).
  • Extension by only one nucleotide is preferable, as it minimizes the overall mass of the extended primer, thereby increasing the resolution of mass differences between alternative SNP nucleotides.
  • mass-tagged ddNTPs can be employed in the primer extension reactions in place of unmodified ddNTPs. This increases the mass difference between primers extended with these ddNTPs, thereby providing increased sensitivity and accuracy, and is particularly useful for typing heterozygous base positions. Mass-tagging also alleviates the need for intensive sample-preparation procedures and decreases the necessary resolving power of the mass spectrometer.
  • the extended primers can then be purified and analyzed by MALDI-TOF mass spectrometry to determine the identity of the nucleotide present at the target SNP position.
  • the products from the primer extension reaction are combined with light absorbing crystals that form a matrix.
  • the matrix is then hit with an energy source such as a laser to ionize and desorb the nucleic acid molecules into the gas-phase.
  • the ionized molecules are then ejected into a flight tube and accelerated down the tube towards a detector.
  • the time between the ionization event, such as a laser pulse, and collision of the molecule with the detector is the time of flight of that molecule.
  • the time of flight is precisely correlated with the mass-to-charge ratio (m/z) of the ionized molecule. Ions with smaller m/z travel down the tube faster than ions with larger m/z and therefore the lighter ions reach the detector before the heavier ions. The time-of-flight is then converted into a corresponding, and highly precise, m/z. In this manner, SNPs can be identified based on the slight differences in mass, and the corresponding time of flight differences, inherent in nucleic acid molecules having different nucleotides at a single base position. For further information regarding the use of primer extension assays in conjunction with MALDI-TOF mass spectrometry for SNP genotyping.
  • SNPs can also be scored by direct DNA sequencing.
  • a variety of automated sequencing procedures can be utilized.
  • the nucleic acid sequences of the present invention enable one of ordinary skill in the art to readily design sequencing primers for such automated sequencing procedures.
  • Commercial instrumentation such as the Applied Biosystems 377, 3100, 3700, 3730, and 3730x1 DNA Analyzers (Foster City, CA), is commonly used in the art for automated sequencing.
  • SSCP single-strand conformational polymorphism
  • DGGE denaturing gradient gel electrophoresis
  • Sequence-specific ribozymes can also be used to score SNPs based on the development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature.
  • the SNP affects a restriction enzyme cleavage site
  • the SNP can be identified by alterations in restriction enzyme digestion patterns, and the corresponding changes in nucleic acid fragment lengths determined by gel electrophoresis SNP genotyping can include the steps of, for example, collecting a biological sample from a human subject (e.g., sample of tissues, cells, fluids, secretions, etc.), isolating nucleic acids (e.g., genomic DNA, mRNA or both) from the cells of the sample, contacting the nucleic acids with one or more primers which specifically hybridize to a region of the isolated nucleic acid containing a target SNP under conditions such that hybridization and amplification of the target nucleic acid region occurs, and determining the nucleotide present at the SNP position of interest, or, in some assays, detecting the presence or absence of an amplification product (assays can be designed so that hybridization and/or amplification will only occur if a particular SNP allele is present or absent).
  • SNP genotyping is useful for numerous practical applications, as described below.
  • Examples of such applications include, but are not limited to, SNP-disease association analysis, disease predisposition screening, disease diagnosis, disease prognosis, disease progression monitoring, determining therapeutic strategies based on an individual's genotype ("pharmacogenomics"), developing therapeutic agents based on SNP genotypes associated with a disease or likelihood of responding to a drug, stratifying a patient population for clinical trial for a treatment regimen, predicting the likelihood that an individual will experience toxic side effects from a therapeutic agent, and human identification applications such as forensics.
  • detecting may carried out by at least one process selected from the group consisting of allele-specific probe hybridization, allele-specific primer extension, allele-specific amplification, sequencing, 5' nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, and single-stranded conformation polymorphism.
  • the invention concerns a kit for use in identifying a woman having an increased risk of developing venous thrombosis, said kit comprising at least one SNP detection reagent for detecting at least one of the SNPs specified in any one of SEQ ID Nos. 1 to 5, or a complement thereof.
  • the SNP detection reagent is an isolated or synthetic DNA oligonucleotide probe or primer, or a RNA oligonucleotide or primer or a PNA oligomer or a combination thereof, that hybridizes to a fragment of a target nucleic acid molecule containing one of the SNPs specified in any one of SEQ ID Nos. 1 to 5, or a complement thereof.
  • said SNP detection reagent can differentiate between nucleic acids having a particular nucleotide at a target SNP position.
  • the SNP detection reagent hybridizes under stringent conditions to at least 8, 10, 12, 16, 18, 20, 22, 25, 30, 40, 50, 55, 60, 65, 70, 80, 90, 100, 120 or more consecutive nucleotides in a target nucleic acid molecule comprising at least one of the SNPs specified in any one of SEQ ID Nos. 1 to 5, or a complement thereof.
  • the at least one SNP detection reagent is an oligonucleotide or primer having a length of at least 8 nucleotides, preferably a length of at least 10, 12, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides.
  • the SNP detection reagent is a compound that is labeled.
  • a method for identifying an agent useful in prophylactically or therapeutically treating venous thrombosis in women comprises
  • the term "artificial experimental model system” identifies that the system is not a native individual but a system reflecting the native situation whereby said system does not exist in nature.
  • the model system may be an in-vitro model system, for example a flow chamber model.
  • an experimental model system can comprise a flow chamber which may comprise a thrombogenic surface or thrombogenic substrate such as a glass cover slip which is provided with a thrombogenic surface, wherein at least a portion of said thrombogenic surface is utilized as field of interest which is examined for thrombogenesis.
  • the advantage of in-vitro models is the consistency of conditions which may be adjusted as desired. Thus, in-vitro model systems provide the utmost reproducibility.
  • said experimental model system may be a cellular model system, preferably a model system comprising mammalian cells, more preferably the cellular model system comprises human cells, most preferably cell of a female humans.
  • a cellular model system allows in-vivo experiments under tightly controllable conditions.
  • said experimental model system may be an animal model system.
  • the animal of the animal model system is preferably a mammal, more preferable a female mammal, even more preferably a human, and most preferably a female human, e.g. in clinical trials. Using an animal model system most closely resembles the clinical situation.
  • leukocytes were extracted from whole blood samples of the persons, and the genomic DNA of the leukocytes was isolated by standard methods.
  • the factor IX gene in particular the known age-related increase element, was analyzed for polymorphisms by PCR amplification and gene sequencing.
  • DNA fragment having a length of about 408 base pairs i.e. 408, 410 or 412 bp, depending on polymorphism rs35599944; corresponding to the nucleotide sequence from postion 308 to 715 within SEQ ID NO: 6) were amplified in that
  • Amplified DNA fragments were purified using the QIAquick PCR Purification Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. Purified DNA was dissolved in nuclease-free water at a concentration of between 10 and 20 ng/ ⁇ l.
  • the data were acquired and administered using Microsoft® ACCESS 2000.
  • the statistical analysis was performed using the program SAS® System 9.13 (Statistical Analysis System GmbH, Heidelberg, Germany).
  • Odds-ratios having confidence intervals of 95% were used as estimate value for the relative risk for venous thrombosis.
  • descriptive statistical methods mean, standard deviation, standard error
  • the significance level was set at p> 0.005.
  • Table 4 Polymorphisms and occurrence of mutations in an area of the F9 gene gender Polymorphism NCBI - SNP-database Genotype Number within collective Male F9 G32023A rs440051 A/- 50 (191) Female F9 G32023A rs440051 A/A 11 (196) G/G 125 (196) G/A 60 (196) Male F9 GT5:32164:6/4 rs35599944 GT4/- 5 (191) GT5/- 136 (191) GT6/- 50 (191) Female F9 GT5:32164:6/4 rs35599944 GT4/GT4 0 (196) GT5/GT5 116 (196) GT6/GT6 11 (196) GT4/GT5 9 (196) GT5/GT6 55 (196) GT4/GT6 5 (196) Table 5: prevalence and relative risk (Odds-ratio) of venous thrombosis in Women associated with variants of two polymorphisms Polymorphism dbSNP ID Genotype, risk factor Venous
  • genotype AA of said F9 G32023A polymorphism is a risk factor for women in encountering a thromboembolism, in particular a risk factor indicating an increased risk for women encountering a thromboembolism at an age of 50 years or older.

Claims (11)

  1. Ein Verfahren zur Identifizierung einer Frau mit erhöhtem Risiko zur Ausbildung einer venösen Thrombose, das Verfahren umfasst die Genotypisierung der Frau in Bezug auf mindestens eines von dem F9 G32023A (rs440051) Polymorphismus und dem F9 5:32164:6/4 Polymorphismus (rs35599944), wobei der Nachweis der Anwesenheit des Genotyps AA von dem F9 G32023A Polymorphismus (rs440051) und/oder des Genotyps GT6/GT6 von dem F9 5:32164:6/4 Polymorphismus (rs35599944) hinweisend ist für ein erhöhtes Risiko zur Ausbildung der venösen Thrombose.
  2. Das Verfahren nach Anspruch 1 zur Identifizierung einer Frau, die von einer prophylaktischen oder therapeutischen Behandlung der venösen Thrombose aufgrund eines erhöhten Risikos zur Ausbildung der venösen Thrombose profitieren kann, das Verfahren umfasst die Genotypisierung der Frau in Bezug auf mindestens eines von dem F9 G32023A Polymorphismus (rs440051) und von dem F9 5:32164:6/4 Polymorphismus (rs35599944), wobei der Nachweis der Anwesenheit des Genotyps AA von dem F9 G32023A Polymorphismus (rs440051) und/oder des Genotyps GT6/GT6 von dem F9 5:32164:6/4 Polymorphismus (rs35599944) hinweisend ist für eine bestimmte prophylaktische oder therapeutische Behandlung der venösen Thrombose aufgrund eines erhöhten Risikos zur Ausbildung der venösen Thrombose.
  3. Das Verfahren nach einem der Ansprüche 1 bis 2, das einen Nachweis beider Genotypen AA vom F9 G32023A Polymorphismus (rs440051) und GT6/GT6 vom F9 5:32164:6/4 Polymorphismus (rs35599944) umfasst.
  4. Das Verfahren nach einem der Ansprüche 1 bis 3, wobei der Nachweis eine Methode beinhaltet ausgewählt aus der Gruppe aus Hybridisierungs-basierten Tests, PCRbasierten Tests, Primer-Extension-Reaktionen, sequenziellen Reaktionen, Allele-spezifische Sonden-Hybridisierung, Allele-spezifischen Primär-Extension, Allele-spezifische Amplifikation, Sequenzierungen, 5' Nuklease-Verdau, Molecular-Beacon-Test, Oligonukleotid-Ligations-Test, Größenanalyse, und Einzelstrang-Konformations-Polymorphismus.
  5. Das Verfahren nach einem der Ansprüche 1 bis 4, in dem die genomische DNA der Frau einer Risikobewertung für den Nachweis der Genotypisierung unterzogen wird.
  6. Die Verwendung eines Kits zur Identifizierung einer Frau mit erhöhtem Risiko zur Ausbildung venöser Thrombose, dieses Kit umfasst mindestens ein SNP Nachweisreagenz für den Nachweis der Anwesenheit von mindestens einem Genotyp AA von dem F9 G32023A Polymorphismus (rs440051) und einem Genotyp GT6/GT6 von dem F9 5:32164:6/4 Polymorphismus (rs35599944).
  7. Die Verwendung eines Kits nach Anspruch 6, wobei das SNP Nachweisreagenz eine isolierte oder synthetische DNA Oligonukleotid-Sonde oder -Primer oder ein RNA Oligonukleotid oder Primer oder ein PNA-Oligomer oder eine Kombination dieser ist, die mit einem Fragment eines Target-Nukleinsäuremoleküls enthaltend einen der SNPs spezifiziert in einer der SEQ ID Nos. 1 bis 5, oder der Komplementären hiervon, hybridisiert.
  8. Die Verwendung eines Kits nach einem der Ansprüche 6 oder 7, wobei das SNP Nachweisreagenz differenzieren kann zwischen Nukleinsäuren mit einer bestimmten Nukleotid an einer SNP-Target-Position.
  9. Die Verwendung eines Kits nach einem der Ansprüche 6 bis 8, wobei das SNP Nachweisreagenz unter stringenten Bedingungen an mindestens 8, 10, 12, 16, 18, 20, 22, 25, 30, 40, 50, 55, 60, 65, 70, 80, 90, 100, 120 oder mehr konsekutiven Nukleotiden in einem Target-Nukleinsäuremolekül, enthaltend mindestens einen der SNPs spezifiziert in einer der SEQ ID Nos. 1 bis 5, oder der Komplementären hiervon, hybridisiert.
  10. Die Verwendung eines Kits nach einem der Ansprüche 6 bis 9, in dem mindestens ein SNP Nachweisreagenz ein Oligonukleotid oder ein Primer ist mit einer Länge von mindestens 8 Nukleotiden, bevorzugt mit einer Länge von mindestens 10, 12, 16, 17, 18, 19, 20, 21, 22, 23, 24 oder 25 Nukleotiden.
  11. Die Verwendung eines Kits nach einem der Ansprüche 6 bis 10, in dem das SNP Nachweisreagenz eine markierte Verbindung ist.
EP12769657.3A 2011-10-07 2012-10-08 Mit venöser thrombose bei frauen assoziierte genetische polymorphismen, nachweisverfahren und ihre verwendung Not-in-force EP2764116B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12769657.3A EP2764116B1 (de) 2011-10-07 2012-10-08 Mit venöser thrombose bei frauen assoziierte genetische polymorphismen, nachweisverfahren und ihre verwendung

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11184398.3A EP2578698A1 (de) 2011-10-07 2011-10-07 Mit venöser Thrombose bei Frauen assoziierte genetische Polymorphismen, Nachweisverfahren und deren Verwendungen
EP12769657.3A EP2764116B1 (de) 2011-10-07 2012-10-08 Mit venöser thrombose bei frauen assoziierte genetische polymorphismen, nachweisverfahren und ihre verwendung
PCT/EP2012/069819 WO2013050585A1 (en) 2011-10-07 2012-10-08 Genetic polymorphisms associated with venous thrombosis in women, methods of detection and uses thereof

Publications (2)

Publication Number Publication Date
EP2764116A1 EP2764116A1 (de) 2014-08-13
EP2764116B1 true EP2764116B1 (de) 2017-03-29

Family

ID=47002869

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11184398.3A Withdrawn EP2578698A1 (de) 2011-10-07 2011-10-07 Mit venöser Thrombose bei Frauen assoziierte genetische Polymorphismen, Nachweisverfahren und deren Verwendungen
EP12769657.3A Not-in-force EP2764116B1 (de) 2011-10-07 2012-10-08 Mit venöser thrombose bei frauen assoziierte genetische polymorphismen, nachweisverfahren und ihre verwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP11184398.3A Withdrawn EP2578698A1 (de) 2011-10-07 2011-10-07 Mit venöser Thrombose bei Frauen assoziierte genetische Polymorphismen, Nachweisverfahren und deren Verwendungen

Country Status (2)

Country Link
EP (2) EP2578698A1 (de)
WO (1) WO2013050585A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3075404A1 (de) 2015-03-30 2016-10-05 Carebay Europe Ltd. Informationsanbieteranordnung zum gebrauch mit einer medikamentenverabreichungsvorrichtung
CN114214402B (zh) * 2021-12-29 2024-02-09 江苏意诺飞生物科技有限公司 血液高凝或静脉血栓风险基因多态性检测引物组、试剂盒及检测方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2915679C (en) 2006-10-20 2017-12-12 Celera Corporation Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
EP2764116A1 (de) 2014-08-13
WO2013050585A1 (en) 2013-04-11
EP2578698A1 (de) 2013-04-10

Similar Documents

Publication Publication Date Title
AU2008283902B2 (en) Novel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the IGF2 gene
US20080305967A1 (en) Genetic Markers Associated with Endometriosis and Use Thereof
US11287425B2 (en) Genetic markers associated with endometriosis and use thereof
US20180105877A1 (en) Genetic polymorphisms associated with depression
US20200087728A1 (en) Genetic markers associated with endometriosis and use thereof
EP2764116B1 (de) Mit venöser thrombose bei frauen assoziierte genetische polymorphismen, nachweisverfahren und ihre verwendung
EP2393939B1 (de) Snp-marker für mamma- und ovarialkarzinomrisiko
AU2010213727A1 (en) Combinations of polymorphisms for determining allele-specific expression of IGF2
KR102158713B1 (ko) Gba 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
US20100003691A1 (en) Genetic Markers Associated with Degenerative Disc Disease and Uses Thereof
KR102158721B1 (ko) Rnf144a 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
JP2007516719A (ja) 一塩基多型を含む二型糖尿病に関与するポリヌクレオチド、それを含むマイクロアレイ及び診断キット、並びにそれを利用したポリヌクレオチドの分析方法
US20140309139A1 (en) Genetic polymorphisms associated with venous thrombosis in women, methods of detection and uses thereof
US20150337373A1 (en) Genetic Markers Associated with Degenerative Disc Disease and Uses Thereof
KR102158716B1 (ko) Arhgap32 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
KR102158725B1 (ko) Mink1 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
US20230257814A1 (en) Methods and kits for treating or diagnosing cannabinoid hyperemesis syndrome
KR102158723B1 (ko) Spcs3 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
KR102158719B1 (ko) Loc102724084 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
US7592141B2 (en) Methods of identifying individuals at reduced risk of sepsis
KR100985984B1 (ko) Ｃｏｌ4ａ3 유전자를 이용한 만성 폐기능 장애 감수성 진단용 조성물 및 이를 이용한 만성 폐기능 장애 감수성 예측 및 판단 방법
EP1538220A2 (de) Allelische varianten des faktor vii gens

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140506

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20150709

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20161021

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 879820

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170415

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012030497

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170630

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170629

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170329

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 879820

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170629

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170731

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170729

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012030497

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20180103

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602012030497

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20171008

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20180629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171031

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171031

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171008

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180501

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171008

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20171031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171031

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171008

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171008

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20121008

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329